ELANIX
LIVE

Serial Number

79212480

Owner

Elanix Biotechnologies SA

Attorney

Lisa M. DuRoss

Filing Date

Mar 7, 2017

Add to watchlist:

No watchlists yet
View on USPTO

ELANIX Trademark

Serial Number: 79212480 • Registration: 5634868

ELANIX is a trademark filed by Elanix Biotechnologies SA on March 7, 2017. The trademark is classified under Class 3 (Cosmetics & Cleaning), Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 10 (Medical Apparatus), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

Elanix Biotechnologies SA

Chemin du Joran 10

Entity Type: 33

Trademark Details

Filing Date

March 7, 2017

Registration Date

December 25, 2018

Published for Opposition

October 9, 2018

Cancellation Date

July 11, 2025

Goods & Services

Pharmaceutical, biological or biotechnological products for curing or treating dermatological, gynecological and orthopedic conditions namely, pharmaceutical preparations for treating dermatological, gynecological and orthopedic conditions; wound dressing containing foetal cell based/derived proteins; protein augmented surfaces for orthopaedic implants, namely, implantable scaffolds comprising living tissue primarily comprised of proteins; wound dressing containing foetal cell based/derived proteins for which the cells were cultured in conditions as to produce these proteins; protein augmented surfaces for orthopaedic implants, namely, implantable scaffolds comprising living tissue primarily comprised of proteins for orthopaedic implants; pharmaceutical, biological or biotechnological preparations, namely, specialty medicated cosmetic creams, wound dressings, implantable scaffolds comprising living tissue for enhancing therapy or maintaining tissue contour, and cell derivatives being stem cells for medical use for tissue regeneration; pharmaceutical, biological or biotechnological preparations for medical use for treatment ofgynecological illnesses; biological or biotechnological preparations for medical use for treatment of orthopedic injuries; Pharmaceutical, biological or biotechnological preparations for medical use for activating cellular functions namely, for treatment of foetal cell derived structural and adhesion proteins to alter immune responses or enhance wound healing, growth supplements for manufacturing of cell therapies

Cosmetic preparations, namely, preparations for cleaning, protecting and maintaining in good condition various parts of the human and animal body surface; cosmetic preparations for regeneration of the skin and mucous membranes; cosmetic preparations for personal use

Matrices for wound dressings in the nature of interactive wound dressings primarily composed of non-living tissue for medical use comprising artificial or organically derived but non-living scaffold materials alone or in combination with cells or cell derivatives to protect the skin and heal skin related conditions, burns, ulcers, cuts, and surgical incisions; Matrices for wound dressings in the nature of interactive wound dressings primarily composed of non-living tissue for medical use comprising artificial or organic gels or creams alone or in combination with non-living cell derivatives to protect the skin and heal skin related conditions burns, ulcers, cuts, and surgical incisions; Matrices for tissue regeneration in the nature of implantable dermatology scaffolds comprising artificial or non-living organic materials alone or in combination with cells or cell derivatives for maintaining tissue contour during tissue regeneration; Matrices in the nature of interactive wound dressings primarily composed of non-living tissue for medical use comprising artificial or non-living organic scaffold materials alone or in combination with cells or cell derivatives to protect gynecologic and urologic intimate zones and heal related conditions, lacerations, dryness, and blistering; Matrices in the nature of interactive wound dressings primarily composed of non-living tissue for medical use comprising artificial or organic gels or creams alone or in combination with cells or cell derivatives to protect gynecologic and urologic intimate zones and heal related conditions, lacerations, dryness, and blistering; Matrices for tissue regeneration in the nature of implantable gynecology scaffolds comprising artificial or non-living organic materials alone or in combination with cells or cell derivatives for maintaining tissue contour during tissue regeneration; Matrices for tissue regeneration comprising artificial or non-living organic scaffold materials alone or in combination with cells or cell derivatives to heal bone, cartilage, tendon related conditions, tendinopathies, and fractures; Matrices for tissue regeneration comprising artificial or organic gels or creams alone or in combination with cells or cell derivatives to heal bone, cartilage, tendon related conditions, tendinopathies, and fractures; Matrices for tissue regeneration in the nature of implantable orthopedic scaffolds comprising artificial or non- living organic materials alone or in combination with cells or cell derivatives for maintaining tissue contour during tissue regeneration

Scientific research consulting services provided by consultants in the fields of pharmaceutical, biological, biotechnological, medical and cosmetic research, preclinical and safety assessments

Custom manufacture of cosmetic preparations, pharmaceutical preparations and/or chemical preparations for use in industry, intermediate and finished formulations, and single constituents; Custom manufacture of biological tissue and of biotechnological products for use in research; Custom manufacture of cosmetics to order and according to customer requirements; Custom manufacture for others of biological production platforms, biotechnology production platforms for protein production, mammalian and human cells for protein production, organoid production for testing purposes, to order and according to customer requirements

Medical services and providing of medical information in the medical field; Medical testing and analysis for diagnostic purposes; Medical consultation services provided by consultants relating to pharmaceutical, biological, biotechnological, cosmetic and medical products

Software for medical applications for diagnosing and monitoring tissue healing in dermatology, orthopedics, and gynecology

Filing History

TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
Mar 11, 2026 INTR
CANCELLED SECTION 71
Jul 11, 2025 C71T
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Dec 25, 2023 REM3
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Jul 11, 2022 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jul 11, 2022 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Jul 11, 2022 ECDR
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Jul 11, 2022 EWAF
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jul 11, 2022 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jul 11, 2022 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Jul 11, 2022 COAR
FINAL DECISION TRANSACTION PROCESSED BY IB
Apr 26, 2019 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Apr 5, 2019 FICS
FINAL DISPOSITION PROCESSED
Apr 5, 2019 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Mar 25, 2019 FICR
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Jan 5, 2019 OPNX
REGISTERED-PRINCIPAL REGISTER
Dec 25, 2018 R.PR
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Dec 19, 2018 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Dec 19, 2018 OPNR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Oct 9, 2018 NPUB
PUBLISHED FOR OPPOSITION
Oct 9, 2018 PUBO
NOTIFICATION PROCESSED BY IB
Oct 6, 2018 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Sep 19, 2018 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Sep 19, 2018 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Sep 19, 2018 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 4, 2018 CNSA
EXAMINER'S AMENDMENT ENTERED
Aug 31, 2018 XAEC
ASSIGNED TO LIE
Aug 31, 2018 ALIE
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Aug 31, 2018 GNEN
EXAMINERS AMENDMENT E-MAILED
Aug 31, 2018 GNEA
EXAMINERS AMENDMENT -WRITTEN
Aug 31, 2018 CNEA
NEW REPRESENTATIVE AT IB RECEIVED
Jun 7, 2018 NREP
NOTIFICATION OF FINAL REFUSAL EMAILED
Mar 1, 2018 GNFN
FINAL REFUSAL E-MAILED
Mar 1, 2018 GNFR
FINAL REFUSAL WRITTEN
Mar 1, 2018 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 14, 2018 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 13, 2018 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 13, 2018 TROA
REFUSAL PROCESSED BY IB
Sep 1, 2017 RFNP
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Aug 17, 2017 RFCS
REFUSAL PROCESSED BY MPU
Aug 17, 2017 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Aug 1, 2017 RFCR
NON-FINAL ACTION WRITTEN
Jul 31, 2017 CNRT
NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW
Jul 29, 2017 RFWR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jul 24, 2017 RFCR
NON-FINAL ACTION WRITTEN
Jul 23, 2017 CNRT
APPLICATION FILING RECEIPT MAILED
Jul 18, 2017 MAFR
ASSIGNED TO EXAMINER
Jul 14, 2017 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 14, 2017 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jul 13, 2017 REPR